FASLG and neoplasm: To exploit the Fas/FasL pathway for broader and more effective CAR T cell targeting even beyond tumors with natural high Fas expression, the group suggested oncolytic viral delivery of Fas to Fas-negative tumor cells to sensitize tumor cells to Fas-mediated bystander lysis.